Conference Menu

Overview
Register
Day 1
Day 2
Download Brochure
Hotel & Travel
Sponsor & Exhibit
Floorplan
Posters
Press Pass
Request Information
Archives 



Corporate Sponsors:

Amarantus Bioscience 

 GYROS 

 

Ora 


Official Media Partner:

Bio-IT-

Word 


Lead Sponsoring Publications:

Gen 

nature 

The Scientist 

Science AAAS 


Sponsoring Publications:

Drug Discovery News  

Insight Pharma Reports 

OphthaBlueLogo 

 

PharmaVoice 


Web Partner:

Labroots   

Pharmcast  

Biospace  

einnews  

GenomeWeb  

FiercePharma  


Targeting Ocular Disorders - Day 1


Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!

Monday, October 6

1:00 pm Registration

2:00 Opening Remarks by Chairperson

James Larrick, MD, Ph.D., Co Founder and Managing Director, Panorama Research Institute, Wntgen LLC & Velocity Pharmaceutical Development LLC

KEYNOTE PRESENTATION

2:10 Systemic Administration of Anti-Ab mAb Reduces Retinal Deposition of Abeta and Activated Complement C3 in Age-Related Macular Degeneration Mouse Model 

Ian R. Catchpole, Ph.D., Topical BioPharm Discovery Research and Development, Glaxo-Smith Kline

Cfh-/- mice were treated systemically in both prophylactic andtherapeutic regimes with an anti-Ab monoclonal antibody (mAb), 6F6, todetermine the effect on the cfh-/- retinalphenotype. Prophylactic treatment with 6F6 demonstrated a dose dependent reduction in the accumulation of both Aband activated C3 deposition. SerumAb levels after systemic administration of 6F6 show accumulation of Ab in the periphery suggestive of a peripheral sinkmechanism. In summary, anti-Ab mAb treatment can partially prevent or reverse ocular phenotypes of the cfh-/- mouse. The data support this therapeutic approach in humans potentially modulating two key elements in the pathogenesis of AMD – Ab and activated, complement C3.

EMERGING THERAPIES FOR RETINAL AND MACULAR DISORDERS

2:40 Oral Therapies for Retinal Degeneration: Case Study of ALK-001

Leonide Saad, Ph.D., CEO, Alkeus Pharmaceuticals, Inc.

Safely attaining biologically active sustained amounts of a compound in the retina is notoriously difficult. Here we present how compounds delivered orally can find their way to the retina. We further discuss the science behind ALK-001, an oral investigational new drug designed to inhibit the formation of toxic by-products thought to be responsible for major retinal degenerations such as AMD, Stargardt, Best disease or autosomal recessive Retinitis Pigmentosa.

3:10 Wnt Pathway Inhibition for Diabetic Retinopathy

James Larrick, MD, Ph.D., Co-Founder and Managing Director, Panorama Research Institute, Wntgen LLC & Velocity Pharmaceutical Development

Activation of the Wnt pathway via LRP6 cell surface signaling contributes to the severe retinal/choroidal neovascularization observed in Vldlr-/- mice. Elevated Wnt signaling is also observed in human retinas of patients with diabetic retinopathy. We identified a novel murine monoclonal antibody that antagonizes LRP6 activity which demonstrates significant activity in numerous animal models of retinal disease. A humanized form of this antibody may be a novel therapy for diabetic retinopathy.

3:40 MANF - A Novel Neurotrophic Factor for the Treatment of Retinal Disorders
Roman Urfer, Ph.D., Chief Development Officer, NeuroAssets Sarl
Mesencephalic astrocyte-derived neurotrophic factor is the prototype of an emerging family of neurotrophic factors with evolutionary highly conserved structure and function. MANF is expressed in response to cellular stress and during retinal development. MANF's activity in genetic and pharmacolocical models of retinal disorders will be presented.
  

3:55 Refreshment Break in the Exhibit Hall with Poster Viewing

4:25 Nanoliter Scaled Immunoassays: Enabling Biomarker Assay Development in Low Volume Ocular Samples
Robert A. Durham, Ph.D., Director, Field Applications North America, Gyros US, Inc.
Biotherapeutic approaches that target diseases of the eye pose a bioanalytical challenge due to the small sample volume of relevant matrices in the target organ. To this end we have evaluated the feasibility of using a nanoliter-scaled immunoassay on the Gyrolab for pharmacokinetic and biomarker assays to support ocular diseased projects. This presentation will review data from Biomarker and PK measurements made in vitreous humor, and tear samples.  The results show that the Gyrolab platform enables development of low volume assays for PK and biomarker measurements in the eye.

 

4:55 Combination Therapy in Diseases of Retinal Origin: A New Paradigm  

David Sherris, Ph.D., CSO, RestorGenex, Corp.

Neovascular retinal and subretinal diseases as in age-related macular degeneration and proliferative diabetic retinopathy occur through a cascade of events over time. Numerous cytokines have shown involvement throughout the disease process. Anti-VEGF technologies inhibit edema and hemorrhage due to their ability to reduce vascular permeability and to some extent inhibit neovascularization. However, VEGF is not the only cytokine in these pathologies. Here we will discuss the influence of a cytokine storm in back-of-the-eye diseases with the example of P529, a first-in-class, allosteric, dual dissociative inhibitor of the TORC1 and TORC2 complexes within the PI3K/Akt/mTOR pathway in combination with anti-VEGF.

5:25 Welcome Reception in the Exhibit Hall with Poster Viewing

6:25 Close of Day



By Series:
By Region:


Conference
& Course Catalog

CHI Catalog 


Short Course DVDs